

## MEDIA ANNOUNCEMENT

### FORMER CEO OF CEPHALON, KEVIN BUCHI JOINS BENITEC BOARD

**SYDNEY Australia, 11 April 2013:** Benitec Biopharma Ltd is pleased to announce that Mr Kevin Buchi, a highly experienced director of US and European pharmaceutical companies, has accepted an invitation to join its Board of Directors.

Benitec is a biopharmaceutical company that develops human therapeutics based on DNA-directed RNA interference (ddRNAi), its unique gene-silencing technology, and Mr Buchi's wealth of experience will make a vital contribution at an important time; Benitec expects to enter the clinic with its Hepatitis C therapeutic later this year.

Based in Pennsylvania, USA, Mr Buchi was formerly CEO of Cephalon, leading the company through its \$US6.8 billion acquisition by Teva Pharmaceutical Industries in 2011, and later serving as Corporate Vice President, Global Branded Products for Teva. He currently serves on the boards of Stemline Therapeutics, Forward Pharma A/S and Alexza Pharmaceuticals, and previously served on the boards of Lorus Therapeutics (Canada), Encysive Pharmaceuticals, Celator Pharmaceuticals and Mesoblast Limited (Australia).

Benitec's Chairman, Mr Peter Francis, encapsulated the significance of Mr Buchi's appointment in this way: "Kevin's impressive track record over 30 years in the international biotechnology and pharmaceutical industry provides Benitec with significant additional business development strength, and importantly, networking capacity in the United States and Europe. The directors and management look forward to working closely with Kevin to achieve the Company's aims through industry partnerships. We see this as a validation of Benitec's corporate strategy over the past few years."

Mr. Buchi, was similarly enthusiastic: "I continue to be impressed with Benitec's programs and progress. The expected entry of the Company's Hepatitis C therapy into the clinic later this year is validation of that progress. I believe that Benitec Biopharma's technology and programs have the potential to bring about a revolution in treatment of many diseases and conditions through the power of DNA-directed RNA interference. I look forward to working with the Company to help advance its exciting programs and vision."

***For more information please contact:***

**Dr Peter French | Chief Executive Officer**

Phone: +61 (02) 9555 6986 | [pfrench@benitec.com](mailto:pfrench@benitec.com) | [www.benitec.com](http://www.benitec.com)

***About Benitec Biopharma Limited:***

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com). ###